Work Here?
Overview
Nucleus Biologics is a biotechnology supplier that provides media and supplements for the cell and gene therapy space. It offers precision cell culture products and tools, manufactured under cGMP standards, to support researchers and clinicians globally. Their products are designed to improve reproducibility in cell culture and enable faster progress from scientific discovery to cures, while delivering transparent information and services. The company differentiates itself by emphasizing reproducibility, clear cGMP-compliant materials, and a willingness to disrupt traditional, outdated practices with a broader environmental focus. The goal is to create a new paradigm that benefits scientists and clinicians, speeds therapy development, and reduces the environmental footprint of cell culture.
About Nucleus Biologics
Industries
Enterprise Software
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Diego, California
Founded
2016
Get referred to Nucleus Biologics
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 5, 2026 CRAIC Formulation Finder broadens NB-Lux adoption among scientists.
- May 12, 2026 NB-Lux claims faster R&D-to-GMP cycles and real-time order visibility.
- February 10, 2026 K500 targets lower costs, easier scale-up, and cleaner manufacturing footprints.
What critics are saying
- GMP software and automation face long validation cycles; a single failure delays revenue.
- K500 sold only two units in February 2026, signaling weak early traction.
- If K500 and NB-Lux fail GMP qualification, Nucleus becomes a niche services vendor.
What makes Nucleus Biologics unique
- May 12, 2026 NB-Lux AI fuses formulation, quoting, manufacturing, and document control.
- February 10, 2026 Krakatoa K500 makes 35–500L media at point-of-use in under three hours.
- January 9, 2025 EXCiPACT plus ISO 9001 certify excipient GMP operations.
Help us improve and share your feedback! Did you find this helpful?
Company News
Nucleus Biologics has launched CRAIC™ Formulation Finder, a large language model assistant for cell culture media and buffer development. The tool allows scientists to describe desired biological outcomes in natural language, and CRAIC™ generates tailored formulation recommendations within minutes based on cell type, phenotype, and manufacturing considerations. The AI assistant integrates with Nucleus Biologics' NB-Lux™ AI platform, enabling users to move directly from formulation discovery to customisation, quoting, and ordering. The system combines LLMs with the company's formulation expertise and manufacturing database, allowing researchers to develop and test optimised formulations within 30 days. "Scientists can now own an optimised media leveraging the human atlas of scientific research," said David Sheehan, founder and CEO. CRAIC™ is currently available within the NB-Lux™ AI platform.
Nucleus Biologics has launched NB-Lux AI, an AI-enabled digital ecosystem for media and buffer manufacturing in advanced therapies. The platform integrates formulation design, feasibility analysis, ordering, manufacturing and documentation into a single continuous workflow, reducing GMP media delivery time to four weeks. Building on the company's 2020 cloud-based ordering portal, NB-Lux AI features AI-driven feasibility analysis, automated quoting, real-time order tracking and a secure document repository called "the Vault" for regulatory filings. The system eliminates manual processes by digitising the entire workflow from formula to GMP release. The platform enables therapy developers to customise formulations whilst maintaining complete ownership and visibility. It integrates directly with Krakatoa manufacturing systems and supports seamless scaling from R&D to Excipient GMP manufacturing.
Nucleus Biologics has launched the Krakatoa K500, a pod-based media and buffer manufacturing system for bioreactor-scale production. The system produces up to 500 litres of sterile solutions in under three hours with less than 15 minutes of hands-on time. The automated system uses preformulated powder-filled pods and a closed single-use workflow to eliminate cold-chain transport, refrigerated storage and centralised media preparation. It features QR-code-driven operation, continuous inline monitoring and automated digital batch record generation for GMP compliance. The San Diego-based company developed the product over six years to reduce costs and complexity in advanced therapy development. Founder David Sheehan said the system aims to create a new paradigm for delivering bioprocessing liquids to bioreactors whilst improving patient access through cost reduction.
Nucleus Biologics launches Krakatoa(R) K500: A pod-based, on-demand media and buffer manufacturing system transforming scale bioproduction. February 10, 2026 SDBN news, syndication comments off on Nucleus Biologics launches Krakatoa(R) K500: A pod-based, on-demand media and buffer manufacturing system transforming scale bioproduction. SAN DIEGO - (BUSINESS WIRE) - #bioprocess - Nucleus Biologics launched the Krakatoa(R) K500, a pod-based, on-demand manufacturing system that produces 35 - 500L of media and buffers at point of use. Click here to view original post
SAN DIEGO, Jan. 9, 2025 /PRNewswire/ - Nucleus Biologics, a leader in precision cell culture media development, is proud to announce that it has achieved an industry-leading quality milestone. It has received EXCiPACT certification for Pharmaceutical Excipients and Pharmaceutical Auxiliary Materials (PAMs) and ISO 9001 certification from SGS. This Excipient GMP certification will better support the cell culture media, buffers, reagents, and supplements needs for our cell and gene therapy customers. This certification, in addition to our ISO 13485 certification, underscores Nucleus Biologics' commitment to delivering the highest quality products that meet the most stringent safety, consistency, and compliance requirements of the biopharmaceutical industry.EXCiPACT is an internationally recognized certification standard specifically designed for excipient manufacturers. It ensures that facilities adhere to the highest standards of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP)
Nucleus Biologics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Nucleus Biologics
Industries
Enterprise Software
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Diego, California
Founded
2016
Nucleus Biologics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today